Eosinophilic Esophagitis (EoE) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Eosinophilic Esophagitis (EoE) Emerging Therapy and TPP Insights

Thelansis’s “Eosinophilic Esophagitis (EoE) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Eosinophilic Esophagitis (EoE) Overview

Eosinophilic Esophagitis (EoE), often characterized as the “asthma of the esophagus,” is a chronic, immune-mediated Type 2 inflammatory disease marked by dense eosinophilic infiltration of the esophageal mucosa, driving progressive structural remodeling and functional impairment. Clinical presentation is highly age-dependent: children frequently present with vomiting, abdominal pain, regurgitation, and feeding difficulties, whereas adolescents and adults typically experience dysphagia, recurrent food impactions, and chest discomfort driven by fibrostenotic narrowing. Diagnosis requires an endoscopic biopsy demonstrating ≥15 eosinophils per high-power field (eos/hpf) isolated to the esophagus. The pathophysiology is strongly linked to atopy, with the vast majority of patients possessing a concurrent history of asthma, eczema, or allergic rhinitis. While historically thought to be unresponsive to acid suppression, modern clinical guidelines now recognize high-dose proton pump inhibitors (PPIs) as a highly effective, first-line anti-inflammatory treatment, utilized alongside targeted dietary allergen elimination and swallowed topical corticosteroids. For patients refractory to conventional therapies or those with severe multi-atopic disease, biologic therapies—most notably the IL-4/IL-13 inhibitor dupilumab—have revolutionized the standard of care by addressing the underlying immunological cascade, while endoscopic dilation remains a critical mechanical intervention for managing established fibrotic strictures.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Eosinophilic Esophagitis (EoE) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026